Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II safety, tolerability and pharmacokinetics study of omadacycline in female patients with uncomplicated Urinary tract infections.

Next Previous
Search
Trial Profile

A Phase II safety, tolerability and pharmacokinetics study of omadacycline in female patients with uncomplicated Urinary tract infections.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omadacycline (Primary)
  • Indications Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Paratek Pharmaceuticals

Most Recent Events

  • 09 May 2018 According to a Paratek Pharmaceuticals media release, phase II UTI data expected in the second half of 2019.
  • 01 Mar 2018 Status changed from planning to recruiting, according to a Paratek media release.
  • 05 Jan 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top